World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
34804
World Ranking
15889
National Ranking
7993

Gregory A. Otterson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gregory A. Otterson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 404 publications — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gregory A. Otterson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gregory A. Otterson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gregory A. Otterson is affiliated with The Ohio State University in the United States. Their research primarily focuses on medicine, with a significant emphasis on oncology. Within this broad field, their work spans subfields including oncology, pulmonary and respiratory medicine, epidemiology, molecular biology, and radiology, nuclear medicine, and imaging.

They have contributed notably to multiple topics within cancer research. These topics encompass cancer immunotherapy and biomarkers, lung cancer treatments and mutations, lung cancer research studies, colorectal cancer treatments and studies, lung cancer diagnosis and treatment, pancreatic and hepatic oncology research, and inflammatory biomarkers in disease prognosis.

Otterson's publication record features numerous articles in a variety of respected journals. Frequent venues for their work include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Journal of the National Comprehensive Cancer Network
  • Cancer Immunology Immunotherapy
  • Clinical Lung Cancer

Notable papers authored or co-authored by Otterson include:

  • Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021, 2021, Journal of the National Comprehensive Cancer Network
  • Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer, 2020, JAMA Oncology
  • NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023, 2023, Journal of the National Comprehensive Cancer Network
  • Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration, 2020, Nature Medicine

Frequent collaborators in Otterson's research include Dwight H. Owen, Carolyn J. Presley, David P. Carbone, Lai Wei, and Mingjia Li. These co-authorships reflect sustained partnerships within the field of oncology.

Best Publications

  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Non–Small Cell Lung Cancer

    David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang

  • Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

    David S. Ettinger;Douglas E. Wood;Dara L. Aisner;Wallace Akerley

  • Non-small cell lung cancer, version 1.2020: Featured updates to the NCCN guidelines

    David S. Ettinger;Douglas E. Wood;Charu Aggarwal;Dara L. Aisner

  • NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    David S. Ettinger;David S. Ettinger;Douglas E. Wood;Douglas E. Wood;Dara L. Aisner;Wallace Akerley;Wallace Akerley

  • Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

    Jacob J. Chabon;Andrew D. Simmons;Alexander F. Lovejoy;Mohammad S. Esfahani

  • Non-small cell lung cancer: Clinical practice guidelines in oncology

    David S. Ettinger;Wallace Akerley;Gerold Bepler;Matthew G. Blum

  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

    Roy S Herbst;Rafat Ansari;Frederique Bustin;Patrick Flynn

  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

    Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  • Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines

    David S. Ettinger;Wallace Akerley;Hossein Borghaei;Andrew C. Chang

  • Non–Small Cell Lung Cancer, Version 6.2015

    David S. Ettinger;Douglas E. Wood;Wallace Akerley;Lyudmila A. Bazhenova

  • NCCN Guidelines ® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines

    David S. Ettinger;Douglas E. Wood;Wallace Akerley;Lyudmila A. Bazhenova

  • Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.

    Samir N. Khleif;James Degregori;Carole L. Yee;Gregory A. Otterson

  • NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

    David S. Ettinger;Dara L. Aisner;Douglas E. Wood;Wallace Akerley

  • Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth

    William R. Sellers;Bennett G. Novitch;Satoshi Miyake;Agnieszka Heith

  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

    Alexander Drilon;Alexander Drilon;Salvatore Siena;Rafal Dziadziuszko;Fabrice Barlesi

  • MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines.

    M. Crawford;E. Brawner;K. Batte;L. Yu

  • Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).

    Ying Zhao;Shaoli Lu;Lipeng Wu;Guolin Chai

  • Malignant pleural mesothelioma.

    David S. Ettinger;Wallace Akerley;Hossein Borghaei;Andrew Chang

Frequent Co-Authors

David P. Carbone
David P. Carbone The Ohio State University
David S. Ettinger
David S. Ettinger Johns Hopkins University
Leora Horn
Leora Horn Vanderbilt University Medical Center
Thomas A. D'Amico
Thomas A. D'Amico Duke University
Peter G. Shields
Peter G. Shields The Ohio State University
Ramaswamy Govindan
Ramaswamy Govindan Washington University in St. Louis
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Wei-Guo Zhu
Wei-Guo Zhu Shenzhen University
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering the broader healthcare field beyond traditional medical degrees, there are several flexible online options to launch or advance your career. Programs like direct entry msn online allow non-nurses to quickly transition into advanced nursing roles, offering an efficient path for career changers. Those looking for more accessible entry points might also explore direct entry nursing programs with fewer prerequisites and a streamlined admissions process.

Allied health careers such as medical billing and coding offer solid job prospects and can be pursued from home. Consider some of the best online medical billing and coding schools if you prefer a non-clinical healthcare role with flexible learning options.

Finally, if standardized testing poses a challenge, certain absn programs that don't require teas can help you bypass some common entrance exams, making the path to a nursing degree more accessible.

Best Scientists Citing Gregory A. Otterson

Trending Scientists

Recently Published Articles